Related Experiment Video

Updated: May 4, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

46.1K

AASLD ISDA Practice Guideline on treatment of chronic hepatitis B

Marc G Ghany1, Calvin Q Pan2, Anna S Lok3

  • 1Clinical Hepatology Research Section, Liver Diseases Branch, National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Hepatology (Baltimore, Md.)
|November 4, 2025
PubMed

Insights

This updated guideline offers evidence-based recommendations for preventing, surveilling, and treating chronic hepatitis B (CHB). It aims to optimize patient care using the GRADE approach for chronic HBV infection management.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Growing data on chronic hepatitis B (CHB) necessitates updated clinical guidelines.
  • The Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach was employed.
  • Focus areas include prevention, surveillance, and treatment strategies for CHB.

Purpose of the Study:

  • To provide updated, evidence-based recommendations for managing chronic hepatitis B.
  • To address key clinical questions in CHB prevention, surveillance, and treatment.
  • To optimize the clinical care of individuals with CHB.

Main Methods:

  • Guideline development followed National Academy of Medicine standards.
  • Structured questions were formulated using the Population, Intervention, Comparison, Outcomes (PICO) framework.
  • Recommendations are supported by four new systematic reviews and two existing ones.

Main Results:

  • Addressed 6 PICO questions on CHB prevention, surveillance, and treatment.
  • Provided recommendations for maternal-infant and horizontal transmission prevention.
  • Included recommendations for liver cancer surveillance and treatment withdrawal in specific patient groups.

Conclusions:

  • This evidence-based guideline offers updated recommendations for CHB care.
  • The guideline aims to optimize management strategies for chronic hepatitis B patients.
  • It serves as a vital resource for healthcare professionals managing CHB.
Abstract

Keywords:
antiviral discontinuationgrey zonehepatocellular carcinomahorizontal transmissionimmune-tolerantindeterminatepregnancysurveillance

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
900
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25